BTIG analyst Marie Thibault raised the firm’s price target on iRhythm (IRTC) to $135 from $120 and keeps a Buy rating on the shares after its ...

BTIG says Carvana (CVNA) reported another strong quarter that shows it is putting more distance between itself and traditional dealer peers.

Wall Street is gearing up for another wave of blank check companies from seasoned and first-time sponsors, showing the ...

BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain ...

When we spoke three years ago, your research was focused on the shopping center, net lease and health care subsectors. Is there anything new or different about your coverage universe here in 2025? Mr.

BTIG lowered the firm’s price target on Evolent Health (EVH) to $20 from $29 but keeps a Buy rating on the shares. The firm notes it was disappointed by the company’s comments around higher ...

As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...

BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am. Discover outperforming stocks and invest smarter with ...

BTIG upgraded Snowflake Inc (NYSE:SNOW) to "Buy" from "Neutral" and introduced a $220 price target on improving demand trends and potential AI-driven growth.

Investing.com -- BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain disruptions that could hamper growth in 2025. The brokerage ...